Membrane interactions and cell selectivity of amphiphilic anticancer peptides

被引：0
作者：
Nyström L. [1 ]
Malmsten M. [1 ,2 ]
机构：
[1] Department of Pharmacy, Uppsala University, Uppsala
[2] Department of Pharmacy, University of Copenhagen, Copenhagen
来源：
Current Opinion in Colloid and Interface Science | 2018年 / 38卷
关键词：
Amphiphilic; Anticancer; Antimicrobial peptide; Membrane;
D O I：
10.1016/j.cocis.2018.06.009
中图分类号：
学科分类号：
摘要：
Following considerable research efforts on antimicrobial effects by cationic and amphiphilic peptides during the last couple of decades, increasing focus has recently been placed on additional host defense and other biological functions by such peptides, such as anti-inflammatory and anticancer effects. Regarding the latter, it has been increasingly understood that amphiphilic peptides present interesting opportunities not only for reaching selective cancer cell toxicity, but also for promoting uptake of other anticancer therapeutics and of nanopariculate delivery systems containing such drugs. While there is an emerging understanding of the direct antimicrobial function of amphiphilic peptides through bacterial membrane destabilization, the mechanisms underlying their anticancer effects remain less clear. Here, we therefore provide a brief overview on factors affecting toxicity of amphiphilic peptides against tumor and non-malignant cells, and also describe how such peptides can be combined with conjugation moieties or drug delivery systems for increased anticancer effects. © 2018 Elsevier Ltd
引用
收藏
页码：1 / 17
页数：16
相关论文
共 87 条
[1]  
Ferrara N., Adamis A.P., Ten years of anti-vascular endothelial growth factor therapy, Nature Rev Drug Disc, 15, pp. 385-403, (2016)
[2]  
Kingwell K., CAR T therapies drive into new terrain, Nature Rev Drug Disc, 16, pp. 301-304, (2017)
[3]  
Gaspar D., Veiga A.S., Castanho M.A.R.B., From antimicrobial to anticancer peptides. A review, Front Microbiol, 4, pp. 1-16, (2013)
[4]  
Dissanayake S., Denny W.A., Gamage S., Sarojini V., Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides, J Control Release, 250, pp. 62-76, (2017)
[5]  
Ruoslahti E., Tumor penetrating peptides for improved drug delivery, Adv Drug Deliv Rev, (2017)
[6]  
Brogden K.A., Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?, Nat Rev Microbiol, 3, pp. 238-250, (2005)
[7]  
Pasupuleti M., Schmidtchen A., Malmsten M., Antimicrobial peptides: key components of the innate immune system, Crit Rev Biotechnol, 32, pp. 143-171, (2012)
[8]  
Hancock R.E., Sahl H.G., Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies, Nat Biotechnol, 24, pp. 1551-1557, (2006)
[9]  
Schmidtchen A., Malmsten M., Peptide interactions with bacterial lipopolysaccharides, Curr Opin Colloid Interface Sci, 18, pp. 381-392, (2013)
[10]  
Hancock R.E.W., Haney E.F., Gill E.E., The immunology of host defense peptides: beyond antimicrobial activity, Nat Rev Immunol, 16, pp. 321-334, (2016)
123456789